Regeneron Pharma and Bayer have begun a China Phase III trial of Eylea™ (aflibercept) Injection, a treatment for neovascular age-related macular degeneration (wet AMD). Earlier this month, Eylea was granted FDA approval for this indication in the US. More details.... Stock Symbol: (NSDQ: REGN) (XETRA: BAY) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});